Business
Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting
Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Nov. 25, 2019\n\n\n\n-  Tumor control rate of 82% in recurrent glioblastoma following one treatment with MDNA55-  Median overall survival of 15 months in patients over-expressing the IL4R-  Meetings with regulatory agencies planned for early 2020\n TORONTO and HOUSTON, Nov. 25, 2019 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, has presented updated clinical results from its Phase 2b trial of MDNA55 in patients with recurrent Glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. \nThe results were presented by Dr. John Sampson, MD, PhD, a Robert H. and Gloria Wilkins Distinguished Professor and Chair of Neurosurgery at Duke University School of Medicine at the 24th Society for Neuro-Oncology (SNO) annual meeting on November 24th, 2019 at the JW Marriott Desert Ridge Resort in Phoenix, Arizona. Dr. Sampson discussed updated efficacy results from the Phase 2b clinical trial of MDNA55 in rGBM patients using the interleukin 4 receptor (IL4R) as an immunotherapy target. IL4R is a biomarker for a more aggressive form of GBM which is overexpressed in 75% of glioblastoma patients, as well as in cells that make up the brain tumor microenvironment (TME).\n\"In this trial, particularly for patients with IL4R over-expression, a prognostic factor that is known to contribute to poor survival, it is gratifying to see that a single treatment with MDNA55 is able to produce impressive survival and tumor control.\"  stated Dr. Sampson. \"By combining precise drug delivery and a targeted therapy, MDNA55 could potentially provide new hope to a large majority of brain cancer patients expressing an important immunotherapeutic biomarker.\" \n\"We are delighted with the results of the Phase 2b trial thus far....